Reven selects eClinical services provider DSG to accelerate Reven’s RJX as treatment for COVID-19
Wednesday September 30, 2020 0 comments
GOLDEN -- Reven Holdings, Inc. today announced it selected DSG, Inc., a leading global eClinical services provider, for all aspects of clinical trial data management during its upcoming COVID-19 study.
Reven is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses—including COVID-19—and inflammatory disorders.
Reven said it is planning to initiate a randomized, double-blind, placebo-controlled, multi-institutional clinical trial of its lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) in the treatment of COVID-19.
The upcoming clinical trial is designed to evaluate the safety and efficacy of RJX in COVID-19 patients.
DSG will work directly with the Reven team, facilitating the real-time process optimizations needed to make data management more efficient in a proactive electronic data capture (EDC) environment.
DSG, with its eCaseLink platform, will provide the data management tools for Reven to achieve its high-quality data collection, management and analysis goals.
Reven said it will also utilize the Interactive Response Technology (IRT) of DSG to manage randomization in the upcoming study.
“I have worked with DSG in several of my previous clinical projects, and I look forward to working once again side by side with their excellent team,” said Fatih Uckun, Reven’s chief medical officer.
“We are confident that using the DSG platforms will enhance the quality of data collection and management during the COVID-19 clinical study,” said Michael Volk, Reven’s chief strategy officer.
“The quality of the clinical trial data is of utmost importance for its reliability and interpretability. Therefore, we selected DSG as our eClinical provider for data management services.”
“The DSG team is thankful for the opportunity to partner with Reven, collaborating with a most effective, practical and talented clinical trial leader, Dr. Fatih Uckun, on systems design, and to be part of the solution in finding a treatment for COVID-19,” said Tony Varano, CEO at DSG.
“This continues the 28-year DSG tradition of continual process improvement and tech innovation for the clinical trials community.
“We believe the eCaseLink unified platform sets the standard for ease of use and flexibility our partners, system users, and stakeholders demand.”